SCHEMBL251637

SCHEMBL251637

CCN(CC)C(=O)c1ccc(Cc2cccc(O)c2N2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 9/20 0.50
OPRM1 P35372 7/20 0.50
OPRK1 P41145 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252533 0.86 OPRD1 (0.53) OPRD1OPRM1OPRK1
SCHEMBL6246739 0.76 HSP90AA1 (0.56)
SCHEMBL6791759 0.74 OPRD1 (0.53) OPRD1OPRM1OPRK1
SCHEMBL8909454 0.73 DRD2 (0.50) OPRD1OPRM1OPRK1
SCHEMBL2052119 0.73 OPRD1 (0.46) OPRD1OPRM1OPRK1
SCHEMBL8394426 0.72 OPRD1 (0.59) OPRD1OPRM1OPRK1
SCHEMBL4577082 0.72 HPGD (0.69) OPRD1OPRM1OPRK1
SCHEMBL8004084 0.72 OPRD1 (0.37) OPRD1OPRM1OPRK1
SCHEMBL6796975 0.72 OPRD1 (0.53) OPRD1OPRM1OPRK1
Hydrochloric Acid SCHEMBL6796027 0.71 OPRD1 (0.58) OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2249872-B1 OLIGOMER-DIARYLPIPERAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2017-03-22 EP disclosed
US-9314463-B2 Oligomer-diarylpiperazine conjugates NEKTAR THERAPEUTICS (US) 2016-04-19 US disclosed
US-20150335640-A1 OLIGOMER-DIARYLPIPERAZINE CONJUGATES NEKTAR THERAPEUTICS 2015-11-26 US disclosed
US-9061026-B2 Oligomer-diarylpiperazine conjugates NEKTAR THERAPEUTICS (US) 2015-06-23 US disclosed
US-20140155412-A1 OLIGOMER-DIARYLPIPERAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2014-06-05 US disclosed
US-20120004242-A1 Oligomer-Diarylpiperazine Conjugates NEKTAR THERAPEUTICS (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155412-A1 OLIGOMER-DIARYLPIPERAZINE CONJUGATES BIRC5, MTX2, IAPP OPRD1 2294/4885OPRM1 574/4885OPRK1 1249/4885
US-20120004242-A1 Oligomer-Diarylpiperazine Conjugates BIRC5, MTX2, IAPP OPRD1 2294/4885OPRM1 574/4885OPRK1 1249/4885
US-20150335640-A1 OLIGOMER-DIARYLPIPERAZINE CONJUGATES BIRC5, MTX2, IAPP OPRD1 2294/4885OPRM1 574/4885OPRK1 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.